Comera Life Sciences Holdings Inc
Change company Symbol lookup
Select an option...
CMRA Comera Life Sciences Holdings Inc
JNJ Johnson & Johnson
AVGO Broadcom Inc
GILD Gilead Sciences Inc
LLY Eli Lilly and Co
ABBV Abbvie Inc
CIEN Ciena Corp
TEAM Atlassian Corp
MRO Marathon Oil Corp
TRGP Targa Resources Corp
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology |
Company profile

Comera Life Sciences Holdings, Inc. is a pre-clinical biotechnology company. The Company is engaged in developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience. Its proprietary formulation platform, SQore, is designed to transform intravenous (IV) biologics into subcutaneous (SQ) versions that patients can self-administer in a single dose. The platform optimizes current versions of subcutaneous biologics and produce biosimilar versions of existing subcutaneous products. It has the potential for broad applications in therapeutic areas dependent on protein-based biologic treatments. The SQore platform includes proprietary structural calculations combined with analytical measurements to guide the selection of excipients for a given protein. The Company’s product programs: CLS-001, a preclinical stage biobetter for Crohn’s and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications.

Price
Delayed
$1.41
Day's Change
-0.09 (-6.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.46
Day's Low
1.40
Volume
(Light)

Today's volume of 1,387 shares is on pace to be much lighter than CMRA's 10-day average volume of 21,683 shares.

1,387

Company Profile

Comera Life Sciences Holdings, Inc. is a pre-clinical biotechnology company. The Company is engaged in developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience. Its proprietary formulation platform, SQore, is designed to transform intravenous (IV) biologics into subcutaneous (SQ) versions that patients can self-administer in a single dose. The platform optimizes current versions of subcutaneous biologics and produce biosimilar versions of existing subcutaneous products. It has the potential for broad applications in therapeutic areas dependent on protein-based biologic treatments. The SQore platform includes proprietary structural calculations combined with analytical measurements to guide the selection of excipients for a given protein. The Company’s product programs: CLS-001, a preclinical stage biobetter for Crohn’s and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications.

Valuation Ratios

No valuation ratios available.

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

November 2022
Current Month
224.5K
Previous Month
274.2K
Percent of Float
2.22%
Days to Cover
4.0324 Days

Share Information

CMRA is in a share class of common stock
Float
13.4M
Shares Outstanding
19.8M
Institutions Holding Shares
18
22.76%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

No company officers listed.

Address

Insider Trading

During the most recent quarter, 201K shares were bought in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.